Arrowhead Pharmaceuticals (ARWR)

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500



NewB76
Forum veteraan
Forum veteraan
Berichten: 1330
Lid geworden op: 21 jul 2018 13:41
waarderingen: 369

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door NewB76 »

Inderdaad CA heeft vele fireside-chat presentation ! ( 3 juni , 10 juni )
Wordt er daar al eens uit de biecht geklapt ? Maar er is vooral de EASL eind juni : met een poster en twee mondelinge voorstellingen !
piddybull liked last!



Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4688
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7953
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

350K in naverkoop en geen centje omhoog?
De smeerlapperij van de beurzen.
Nu toch al de tweede of derde maal op korte termijn.

Het hoort erbij maar op zich is het de donkere zijde van de beurswereld.
Koop of verkoop jij maar even 5000 stuks aan dezelfde koers ...
Benieuwd hoe je de koers zal zien wegschieten.

Anderzijds zijn deze acties vaak een voorbode van belangrijke veranderingen.
We moeten er dus blij van worden :roll:
Arrowhead (ARWR) diversification is only important if you don't do your own work.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4688
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7953
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Jun 3, 2021 at 7:30 AM EDT
PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Jun. 3, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG). Arrowhead also intends to initiate a Phase 2b study and a Phase 3 study of ARO-APOC3 in two additional patient populations in 2021.

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “There are approximately four million people in the United States alone with triglyceride levels greater than 500 mg/dL. Current treatments such as fibrates and fish oils generally seem to provide only modest reductions in triglycerides, and many people remain uncontrolled and at risk of developing pancreatitis. We believe there remains a significant need for new therapies that can substantially lower and sustain triglyceride levels in patients with severe hypertriglyceridemia. We reported initial results from a Phase 1 clinical trial of ARO-APOC3 at the American Heart Association Scientific Sessions in 2020. These results indicated that ARO-APOC3 reduced triglyceride levels by up to 92% with a long duration of effect that was maintained for longer than 12 weeks after the second dose. Importantly, ARO-APOC3 appeared to show consistent activity in various patient populations with a range of different baseline triglyceride levels. These encouraging results provide us with great confidence as we begin a Phase 2b clinical study, AROAPOC3-2001, in patients with severe hypertriglyceridemia to identify an optimal dose and regimen for later stage clinical trials.”

AROAPOC3-2001 is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of ARO-APOC3 in adults with SHTG. Three dose levels of ARO-APOC3 (10 mg, 25 mg and 50 mg) will be evaluated against placebo in participants who have mean fasting triglycerides of greater than or equal to 500 mg/dL (5.65 mmol/L) at screening. A total of approximately 300 participants will be enrolled in the study. All dose cohorts will enroll in parallel with 100 participants per dose cohort randomly assigned in a 3:1 ratio to receive ARO-APOC3 or placebo. Each participant will receive subcutaneous injections on day 1 and week 12. The duration of the study is approximately 54 weeks from screening to the week 48 end-of-study examination. The primary objective of the study is to evaluate the safety and efficacy of ARO-APOC3 in adults with SHTG and to select a dosing regimen for later stage clinical studies in this patient population.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
NewB76 liked last!
Arrowhead (ARWR) diversification is only important if you don't do your own work.

Gebruikersavatar
maartenverhoeve
Forum veteraan
Forum veteraan
Berichten: 1587
Lid geworden op: 02 jan 2012 21:42
waarderingen: 378

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door maartenverhoeve »

piddybull schreef:
03 jun 2021 13:33
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Jun 3, 2021 at 7:30 AM EDT
PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Jun. 3, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG). Arrowhead also intends to initiate a Phase 2b study and a Phase 3 study of ARO-APOC3 in two additional patient populations in 2021.

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “There are approximately four million people in the United States alone with triglyceride levels greater than 500 mg/dL. Current treatments such as fibrates and fish oils generally seem to provide only modest reductions in triglycerides, and many people remain uncontrolled and at risk of developing pancreatitis. We believe there remains a significant need for new therapies that can substantially lower and sustain triglyceride levels in patients with severe hypertriglyceridemia. We reported initial results from a Phase 1 clinical trial of ARO-APOC3 at the American Heart Association Scientific Sessions in 2020. These results indicated that ARO-APOC3 reduced triglyceride levels by up to 92% with a long duration of effect that was maintained for longer than 12 weeks after the second dose. Importantly, ARO-APOC3 appeared to show consistent activity in various patient populations with a range of different baseline triglyceride levels. These encouraging results provide us with great confidence as we begin a Phase 2b clinical study, AROAPOC3-2001, in patients with severe hypertriglyceridemia to identify an optimal dose and regimen for later stage clinical trials.”

AROAPOC3-2001 is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of ARO-APOC3 in adults with SHTG. Three dose levels of ARO-APOC3 (10 mg, 25 mg and 50 mg) will be evaluated against placebo in participants who have mean fasting triglycerides of greater than or equal to 500 mg/dL (5.65 mmol/L) at screening. A total of approximately 300 participants will be enrolled in the study. All dose cohorts will enroll in parallel with 100 participants per dose cohort randomly assigned in a 3:1 ratio to receive ARO-APOC3 or placebo. Each participant will receive subcutaneous injections on day 1 and week 12. The duration of the study is approximately 54 weeks from screening to the week 48 end-of-study examination. The primary objective of the study is to evaluate the safety and efficacy of ARO-APOC3 in adults with SHTG and to select a dosing regimen for later stage clinical studies in this patient population.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Mooi nieuws dat ze ook deze fase opstarten maar het is niet het nieuws waarop we zitten te wachten. Nog even geduld.
piddybull liked last!
In port; Enwave, Ageas, Western Cop, Retail estate, RDS, kbca, roularta, Tessenderlo.,oci, Forfarmers, American airlines en veel arrowhead pharma....

NewB76
Forum veteraan
Forum veteraan
Berichten: 1330
Lid geworden op: 21 jul 2018 13:41
waarderingen: 369

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door NewB76 »

Blijkbaar pittig fireside chat !

Gebruikersavatar
maartenverhoeve
Forum veteraan
Forum veteraan
Berichten: 1587
Lid geworden op: 02 jan 2012 21:42
waarderingen: 378

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door maartenverhoeve »

We zijn in blijde verwachting op hun PB's. De koers klimt laatste week dagelijks met 3-5 % onder een stevig volume! Hopelijk in de zomer een 100-bagger! Ik twijfel er eigenlijk niet aan als je hun pijplijne en gepresteerde performance bekijkt! Dank aan Piddy voor de actieve opvolging en de postings!
VWarena liked last!
In port; Enwave, Ageas, Western Cop, Retail estate, RDS, kbca, roularta, Tessenderlo.,oci, Forfarmers, American airlines en veel arrowhead pharma....

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4688
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7953
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Opvolging is nuttig tijdverdrijf maar zoals met bijna alles in mijn leven soms overdreven.
Hopelijk lazen jullie bijdrage van bioboyscout ook .Toch echt opmerkelijk persoon en terecht echt erg hoog aantal duimpjes op Yahoo.
Zijn post verdient hier te staan.
Ondertussen toch echt wat genieten van ARWR in zijn beste doen.
Voor mij lijkt het zo vanzelfsprekend en voorspelbaar dat dit bedrijf wel zal doen waar mijn vorige helaas toch minstens deels faalde.

Het vuurwerk gaat binnen de maand wel van start.
Hopelijk blijft de markt wel wat stabiel.
Fijn weekend allen.
NewB76 liked last!
Arrowhead (ARWR) diversification is only important if you don't do your own work.

ancaoli
Forum elite
Forum elite
Berichten: 2200
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1236

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door ancaoli »

Gefeliciteerd Piddy, de champagne is voor u dit WE😉. Mooie heropleving bij ARWR. Bij Sorrento 4 PR’s met weinig effect op de koers. 2 mooie bedrijven! Ik kijk alvast uit naar de eerste stand van ons wedstrijdtje ;)
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 4688
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7953
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door piddybull »

Schermafbeelding 2021-06-06 om 20.02.36.png
Schermafbeelding 2021-06-06 om 20.03.15.png
U kunt zich hier registreren waarna u de bijlage kunt bekijken.
NewB76 liked last!
Arrowhead (ARWR) diversification is only important if you don't do your own work.

BillBull
Forum newbie
Forum newbie
Berichten: 4
Lid geworden op: 24 feb 2021 10:55
waarderingen: 0

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door BillBull »

$ARWR:
Fair value: $69
Average yearly return: +69%
:o









Plaats reactie